AV 101

Drug Profile

AV 101

Alternative Names: 4-Chlorokynurenine - VistaGen; 4-CL-KYN; 7-Cl-KYNA; AV-101; L-4-chlorokynurenine; L-4-CI-KYN

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Artemis Neuroscience
  • Developer National Institute of Mental Health; VistaGen Therapeutics
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Phase I Epilepsy; Neuropathic pain; Parkinson's disease
  • Research Huntington's disease; Neurological disorders

Most Recent Events

  • 14 Aug 2017 VistaGen Therapeutics anticipates receiving fast track designation from the US FDA for AV 101 in Major depressive disorder (Adjunctive treatment) in the second half of 2017
  • 29 Jun 2017 VistaGen files an IND application with the US FDA for Major depressive disorders before June 2017
  • 29 Jun 2017 VistaGen Therapeutics announces intention to obtain Fast Track designation for AV 101 as an adjunctive treatment for Major depressive disorder by the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top